For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia TARRYTOWN, N.Y., March 11, 2024 Regeneron Pharmaceuticals, Inc. announced the.